LIPELLA PHARMACEUTICALS INC. Financial Ratios
LIPO|FY2024 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2024 SEC 10-K data.
Key Data Points
- Altman Z-Score -8.99 (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2024)
Return on Equity
-261.3%
Profit Margin
-935.2%
Net Income / Revenue
Asset Turnover
0.20
Revenue / Total Assets
Equity Multiplier
1.39
Total Assets / Equity
Composite: -261.3% (reported: -261.3%)
Profitability
Liquidity
Current Ratio
3.47
Quick Ratio
3.47
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.20
Inventory Turnover
-
Days Sales Outstanding
58 days
As of FY2024 · SEC Form 10-K · Last checked Jun 29, 2026
Earnings Quality
Accrual Ratio
-34.1%
+7.0pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.